Literature DB >> 9604072

Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure.

S D Anker1, M Volterrani, K R Egerer, C V Felton, W J Kox, P A Poole-Wilson, A J Coats.   

Abstract

Tumour necrosis factor alpha (TNF alpha) is increased in patients with cardiac cachexia, a condition associated with reduced peripheral blood flow both at rest and after interventions causing vasodilation. By contrast, in patients with chronic heart failure (CHF), higher TNF levels are associated with a greater capacity for vasodilation in the arm. To clarify the relationship between peripheral blood flow and TNF in CHF, we studied the relation between TNF alpha and blood flow in the leg (plethysmography, post maximal exercise and 5 min ischaemia) in 34 patients (age 63 +/- 2 years, ejection fraction 29 +/- 3%, peak VO2 16.6 +/- 1.1 ml/kg/min, mean +/- SEM). Peak leg blood flow correlated significantly with total TNF alpha (r = 0.68, p < 0.0001, peak VO2 (r = 0.54), and soluble TNF receptors 1 (r = 0.56) and 2 (r = 0.52, all p < 0.002). TNF alpha, soluble TNF receptors 1 and 2 and aldosterone correlated with peak blood flow independently of age, ejection fraction, peak VO2 and functional NYHA class. TNF alpha was the only parameter that showed strong correlations for peak blood flow in all clinically relevant subgroups (severe vs. mild, ischaemic vs. dilated, cachectic vs. non-cachectic patients). This study shows a close and inverse relationship between peak leg blood flow and the plasma concentration of TNF alpha, suggesting a pathophysiological role for TNF alpha in reducing peak peripheral blood flow in CHF.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9604072     DOI: 10.1093/qjmed/91.3.199

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  6 in total

Review 1.  Statins and the role of nitric oxide in chronic heart failure.

Authors:  Stephan von Haehling; Stefan D Anker; Eberhard Bassenge
Journal:  Heart Fail Rev       Date:  2003-01       Impact factor: 4.214

Review 2.  Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications.

Authors:  A P Bolger; S D Anker
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

3.  Calcium glycerophosphate preserves transepithelial integrity in the Caco-2 model of intestinal transport.

Authors:  Palika Datta; Margaret T Weis
Journal:  World J Gastroenterol       Date:  2015-08-14       Impact factor: 5.742

Review 4.  Recent insights into the role of tumor necrosis factor in the failing heart.

Authors:  D L Mann
Journal:  Heart Fail Rev       Date:  2001-03       Impact factor: 4.214

Review 5.  Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology.

Authors:  Catherine Pavoine; Françoise Pecker
Journal:  Cardiovasc Res       Date:  2009-01-28       Impact factor: 10.787

6.  The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study.

Authors:  Piotr Rozentryt; Stephan von Haehling; Mitja Lainscak; Jolanta U Nowak; Kamyar Kalantar-Zadeh; Lech Polonski; Stefan D Anker
Journal:  J Cachexia Sarcopenia Muscle       Date:  2010-10-26       Impact factor: 12.910

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.